|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 403.09 Million
|
|
Market Size (2030)
|
USD 538.63 Million
|
|
CAGR (2025-2030)
|
4.94%
|
|
Fastest Growing Segment
|
Branded
|
|
Largest Market
|
Kanto
|
Market Overview
Japan Gastrointestinal Drugs Market was valued at
USD 403.09 Million in 2024 and is expected to reach USD 538.63
Million by 2030 with a CAGR of 4.94% during the forecast period. The Japan
gastrointestinal drugs market is driven by several key factors. The aging
population in Japan is increasing the prevalence of gastrointestinal disorders,
including acid reflux, ulcers, and inflammatory bowel diseases, creating a
higher demand for effective treatments. Advances in pharmaceutical research and
development are leading to the introduction of innovative drugs with improved
efficacy and safety profiles, further boosting market growth. The rise in
healthcare awareness and the availability of over-the-counter medications are
contributing to market expansion. Government initiatives and healthcare reforms
aimed at improving patient care and accessibility are also playing a role. Collaborations between pharmaceutical
companies and research institutions are enhancing drug discovery and
development, supporting market progression. These factors combined are shaping
the growth trajectory of the gastrointestinal drugs market in Japan.
Key Market Drivers
Rising Incidence of Gastrointestinal Disorders
The prevalence of gastrointestinal disorders in
Japan is increasingly concerning, influenced by a complex interplay of
lifestyle changes, dietary habits, and rising stress levels. These factors
collectively contribute to the growing incidence of conditions such as
inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and liver
diseases, thereby amplifying the demand for effective gastrointestinal drugs. Lifestyle
changes, including sedentary behavior and altered daily routines, are
significant contributors to gastrointestinal health issues. The modern Japanese
lifestyle, characterized by long working hours and high levels of occupational
stress, has led to a more sedentary lifestyle, which can adversely affect
digestive health. Prolonged periods of inactivity are linked to issues like
constipation and obesity, which can exacerbate gastrointestinal disorders. The
increase in sedentary behavior correlates with higher stress levels, which are
known to impact gut health negatively. Stress can disrupt the gastrointestinal
tract's normal function, leading to conditions like IBS, where stress often
exacerbates symptoms. According to a study in “The burden of
gastrointestinal diseases in Japan, 1990–2019, and projections for 2035”, since
1990, cancer has been the leading cause of gastrointestinal disease-related
mortality and disability-adjusted life years (DALYs) in Japan, accounting for
77.1% and 71.2% of these metrics in 1990, and 79.2% and 73.7% in 2019,
respectively. While age-standardized mortality rates and DALYs associated with
cancer have decreased, crude rates have risen, indicating that Japan's aging
population significantly impacts the disease burden. Consequently, the overall
burden of gastrointestinal diseases is projected to increase by 2035. In 1990,
the death rate was 144.7 per 10,000, which rose to 225.8 in 2019, with an
estimated figure of 262.7 by 2035. Similarly, DALYs per 10,000 increased from
3581.6 in 1990 to 3889.5 in 2019, with a projected estimate of 3830.9 by 2035.
The leading causes of death have shifted from stomach cancer, colorectal
cancer, and cirrhosis in 1990 to stomach cancer, colorectal cancer, and liver
cancer in 2019, with projections for 2035 likely to include colorectal cancer,
stomach cancer, and pancreatic cancer.
Dietary habits are another crucial factor
influencing gastrointestinal health in Japan. Traditional Japanese diets, which
were once rich in vegetables, fish, and rice, are increasingly being replaced
by more Westernized eating patterns. The rising consumption of processed foods,
high in fats, sugars, and artificial additives, contributes to gastrointestinal
problems. These dietary changes are associated with an increase in
gastrointestinal disorders such as GERD, peptic ulcers, and dyspepsia. The
growing popularity of convenience foods and fast food has led to irregular
eating patterns, which can disturb digestive processes and contribute to issues
like gastritis and chronic constipation. The prevalence of inflammatory bowel
disease (IBD), including Crohn's disease and ulcerative colitis, has been on
the rise in Japan. IBD is a group of chronic disorders characterized by
inflammation of the gastrointestinal tract, which can lead to severe symptoms
such as abdominal pain, diarrhea, and weight loss. The increasing incidence of
IBD in Japan is partly attributed to changes in environmental factors and
lifestyle, including diet and stress. IBD often requires long-term management
with specialized medications to control inflammation and maintain remission,
driving demand for effective and innovative therapeutic options.
Government Initiatives and Healthcare Reforms
The Japanese government significantly influences
the gastrointestinal drugs market through a series of targeted initiatives and
reforms designed to enhance healthcare quality, expand accessibility, and
foster innovation. One of the primary ways the government contributes to the
market is by expanding healthcare insurance coverage. Japan’s universal
healthcare system ensures that all residents have access to medical services,
and ongoing reforms aim to make coverage more comprehensive and reduce
out-of-pocket expenses for patients. This expanded insurance coverage improves
accessibility to treatments for gastrointestinal disorders, making it easier
for individuals to receive necessary care and adhere to prescribed therapies. The
government has implemented policies to enhance the quality of care while
managing healthcare costs. Value-based pricing and reimbursement systems link
drug prices to their clinical benefits and cost-effectiveness, encouraging the
development of high-value medications. This approach ensures that new
gastrointestinal drugs not only meet rigorous efficacy and safety standards but
also provide meaningful improvements in patient outcomes. Government support
extends to research funding and public health programs, which stimulate
innovation and ensure that cutting-edge treatments are available to a broader
segment of the population. Stringent regulatory standards enforced by the
Pharmaceuticals and Medical Devices Agency (PMDA) ensure that all drugs,
including gastrointestinal medications, adhere to high safety and efficacy
benchmarks. These regulations foster confidence in new products, enhance market
growth, and drive continued advancements in gastrointestinal therapeutics.
Growth of Over-the-Counter (OTC) Medications
The increasing availability and acceptance of
over-the-counter (OTC) gastrointestinal medications are reshaping the
gastrointestinal drugs market by providing a more convenient and accessible
option for managing common issues like heartburn, indigestion, and mild
diarrhea. OTC drugs are particularly appealing to consumers who prefer
self-medication, allowing them to address symptoms without the need for a
doctor’s visit or prescription. This preference is driven by a desire for immediate
relief and the convenience of purchasing medications directly from pharmacies,
supermarkets, or online platforms. The ease of access to these medications,
coupled with their effectiveness in treating mild to moderate gastrointestinal
symptoms, has led to a significant rise in their use. As more consumers opt for
OTC solutions, the market for gastrointestinal drugs expands, reaching a
broader audience. This trend not only makes treatment more accessible but also
shifts some of the burden of gastrointestinal care from healthcare
professionals to consumers, reflecting a growing inclination towards
self-managed health solutions.
Collaborations and Partnerships
Collaborations between pharmaceutical companies,
research institutions, and healthcare providers are increasingly pivotal in
advancing the development of gastrointestinal drugs. These strategic
partnerships are instrumental in fostering innovation and accelerating the drug
development process, which is crucial given the complexity and specificity of
gastrointestinal conditions. One of the primary benefits of these
collaborations is the exchange of expertise and resources. Pharmaceutical
companies bring extensive experience in drug development, regulatory affairs,
and commercialization, while research institutions offer cutting-edge
scientific research, advanced technology, and insights into disease mechanisms.
Healthcare providers contribute clinical expertise and an understanding of
patient needs. By pooling these diverse resources, partners can tackle complex
challenges more effectively, leading to the development of novel treatments.
For example, research institutions might provide advanced preclinical models
and novel biomarkers, while pharmaceutical companies contribute their drug
formulation and delivery technologies.
Strategic alliances and joint ventures enable
companies to streamline and expedite the drug development process.
Collaborative efforts can reduce the time and cost associated with bringing new
gastrointestinal therapies to market. For instance, partnerships may involve
shared clinical trial resources, which can enhance the efficiency of clinical
testing phases. Collaborative agreements often allow for the simultaneous
development of complementary therapeutic strategies, such as combining novel
drug candidates with new drug delivery systems or diagnostics. This
acceleration is vital in addressing urgent unmet medical needs and capitalizing
on emerging scientific discoveries. Collaboration allows companies to leverage
their complementary strengths, which can significantly enhance the development
and commercialization of gastrointestinal drugs. For example, a pharmaceutical
company with strong drug development capabilities might partner with a research
institution specializing in gastrointestinal diseases to develop a new drug
based on the latest scientific findings. Similarly, partnerships between
biotech firms and established pharmaceutical companies can combine innovative
drug discovery with robust commercialization strategies. These synergies enable
partners to overcome individual limitations and create more effective and
comprehensive solutions for gastrointestinal disorders.
Download Free Sample Report
Key Market Challenges
High Costs of Drug Development
The high costs associated with the research and
development (R&D) of gastrointestinal drugs pose a significant challenge.
Developing new gastrointestinal therapies involves extensive research,
preclinical studies, and multiple phases of clinical trials, each of which requires
substantial financial investment. The complexity of gastrointestinal diseases
often necessitates advanced research techniques and longer study durations to
establish the safety and efficacy of new treatments. The financial burden of
R&D is compounded by the need for specialized expertise and technology,
which increases the overall cost. The high risk of failure in clinical trials
means that many drug development projects do not reach the market, leading to
further financial losses. This high cost of drug development can limit the
ability of smaller pharmaceutical companies and startups to participate in the
market and can also impact the affordability of new drugs, posing a challenge
to market growth and innovation.
Regulatory Hurdles and Market Access
Navigating the regulatory landscape in Japan
presents a significant challenge for pharmaceutical companies in the
gastrointestinal drugs market. Japan has stringent regulatory requirements
enforced by the Pharmaceuticals and Medical Devices Agency (PMDA) that demand
rigorous clinical trials, comprehensive safety and efficacy data, and detailed
documentation. The approval process for new gastrointestinal drugs can be
lengthy and costly, involving multiple phases of clinical testing to ensure
that the drugs meet Japan’s high safety standards. This extended approval
timeline can delay the entry of innovative treatments into the market,
affecting companies' ability to capitalize on new opportunities and potentially
diminishing the market's dynamism. Post-marketing surveillance requirements and
the need for continuous reporting on drug safety can add further complexities
and costs. Companies must navigate these regulatory hurdles while balancing the
need for innovation and speed to market, making regulatory compliance a
critical challenge in the Japan gastrointestinal drugs market.
Key Market Trends
Advancements in Drug Research and Development
Continuous innovations in pharmaceutical research
and drug development are profoundly shaping the gastrointestinal drugs market
in Japan, reflecting a concerted effort by companies to address complex
gastrointestinal conditions with advanced therapeutic solutions. This dynamic
environment is characterized by significant investments in research and
development (R&D), aimed at creating therapies with superior efficacy,
reduced side effects, and enhanced delivery systems. Pharmaceutical companies
in Japan are dedicating substantial resources to R&D to advance
gastrointestinal treatments. This investment is driven by the need to address
the limitations of existing therapies and to meet the growing demand for more
effective and safer treatments. Companies are exploring new scientific
frontiers, from molecular biology to advanced drug delivery technologies, to
develop innovative drugs that can better manage a range of gastrointestinal
conditions. This commitment to R&D not only supports the creation of novel
therapies but also contributes to the overall growth and competitiveness of the
gastrointestinal drugs market. Recent breakthroughs in targeted therapies are
transforming the treatment landscape for gastrointestinal disorders. Targeted
therapies aim to address specific molecular targets involved in the
pathogenesis of diseases, offering a more precise approach to treatment. For
instance, in conditions like inflammatory bowel disease (IBD), targeted
biologics that inhibit specific inflammatory cytokines have shown promise in
reducing disease activity and improving patient outcomes. These therapies are
designed to modulate the immune system more precisely, leading to fewer side
effects compared to traditional treatments. The introduction of such targeted
therapies is significantly enhancing the management of complex gastrointestinal
disorders and driving market growth by providing options that address specific
disease mechanisms. EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd.
specializing in gastrointestinal diseases, and Kissei Pharmaceutical Co., Ltd.
The company has announced the launch of “CAROGRA Tablets” (carotegrast methyl;
“CAROGRA”) for the treatment of ulcerative colitis in Japan. This follows the
drug's inclusion in the National Health Insurance Drug Price List effective May
25, 2022.
Biologics represent another major advancement in
gastrointestinal drug development. These complex molecules, including
monoclonal antibodies and recombinant proteins, have revolutionized the
treatment of various gastrointestinal conditions by targeting specific pathways
involved in disease progression. For example, biologics have been particularly
effective in managing severe cases of Crohn’s disease and ulcerative colitis,
where conventional drugs may be insufficient. The development of biologics
involves sophisticated technology and extensive clinical research, resulting in
therapies that offer improved efficacy and safety profiles. As biologics become
more prevalent, they contribute to the expansion of treatment options and the
evolution of the gastrointestinal drugs market in Japan. Innovation in drug
delivery systems is also playing a crucial role in the gastrointestinal drugs
market. Novel formulations, such as controlled-release and extended-release
formulations, are designed to enhance drug absorption and maintain therapeutic
levels over extended periods. These advancements improve patient compliance by
reducing the frequency of dosing and minimizing side effects associated with
peak drug levels. For instance, new formulations of existing drugs can offer
improved stability in the gastrointestinal tract, ensuring better absorption and
effectiveness.
Technological Innovations in Drug Delivery Systems
Advances in drug delivery technologies are
revolutionizing the gastrointestinal drugs market by significantly improving
both the efficacy of treatments and the overall patient experience. These
innovations address critical challenges related to drug stability,
bioavailability, and patient adherence, leading to enhanced therapeutic
outcomes and increased satisfaction among patients.
Controlled-release formulations represent a major
advancement in drug delivery technology, particularly beneficial for
gastrointestinal medications. These formulations are designed to release the
active ingredient at a specific rate over an extended period. This approach
helps maintain optimal drug levels in the bloodstream, ensuring consistent
therapeutic effects while minimizing the need for frequent dosing. For
gastrointestinal drugs, controlled-release formulations can enhance drug
stability in the digestive tract and improve absorption, particularly for drugs
that are sensitive to the acidic environment of the stomach. By reducing the
frequency of dosing and providing a more stable drug delivery,
controlled-release formulations address the issue of patient non-compliance and
improve overall treatment efficacy. Targeted drug delivery systems are another
groundbreaking innovation in the gastrointestinal drugs market. These systems
are engineered to direct drugs precisely to their intended site of action
within the gastrointestinal tract, minimizing systemic exposure and reducing
side effects. For instance, enteric-coated tablets are designed to bypass the
stomach and release the drug only in the intestines, which is particularly
useful for drugs that could be degraded by stomach acid. Advanced delivery
systems, such as nanoparticles or liposomes, can encapsulate drugs and release
them in a controlled manner at specific locations within the gastrointestinal
tract. This targeted approach enhances the drug’s efficacy by concentrating its
effects where they are most needed and reduces adverse reactions associated
with broader systemic exposure.
Segmental Insights
Type Insights
Based on the type, branded
medications currently dominate, although generics are increasingly gaining
ground. This dominance of branded drugs is attributable to several key factors
including their perceived efficacy, extensive clinical validation, and robust
market presence. Branded drugs, often developed by large multinational
pharmaceutical companies, benefit from significant investments in research and
development, leading to the introduction of innovative therapies that offer
superior efficacy and safety profiles. These drugs are frequently associated
with advanced drug delivery systems and cutting-edge formulations, which
contribute to their high market share. Branded medications often have strong
brand recognition and loyalty among healthcare providers and patients, further
solidifying their dominance.
The extensive clinical
trials and regulatory approval processes that branded drugs undergo add to
their credibility and acceptance. In Japan, where stringent regulatory
standards are enforced by the Pharmaceuticals and Medical Devices Agency
(PMDA), branded drugs often have a well-established track record of
effectiveness and safety. This rigorous approval process not only ensures
high-quality standards but also builds confidence in these medications among
healthcare professionals and patients, who are more likely to trust and
prescribe established branded products over newer generics. Branded drugs
typically benefit from significant marketing and promotional efforts, which
enhance their visibility and appeal. Pharmaceutical companies invest heavily in
marketing campaigns, educational initiatives for healthcare providers, and
direct-to-consumer advertising to promote their branded drugs. This extensive
promotion contributes to higher market penetration and sustained demand for
branded products. Branded drugs often come with extensive support services,
such as patient assistance programs and comprehensive prescribing information,
which add value and reinforce their market dominance.
Drug Class Insights
Based on Drug Class, Proton
Pump Inhibitors (PPIs) are currently the dominant force in the Japan
gastrointestinal drugs market. PPIs have established themselves as the leading
class of medication due to their effectiveness in treating a range of
acid-related disorders, including gastroesophageal reflux disease (GERD),
peptic ulcers, and Zollinger-Ellison syndrome. Their widespread use and significant
impact on patient outcomes have solidified their position at the forefront of
gastrointestinal therapeutics. The primary reason for the dominance of PPIs is
their superior efficacy in reducing gastric acid production. By irreversibly inhibiting
the proton pump in the stomach lining, PPIs significantly lower the production
of gastric acid, providing relief from symptoms associated with excessive acid
production. This mechanism of action makes PPIs highly effective for conditions
such as GERD, where acid reflux causes chronic heartburn and damage to the
esophageal lining. PPIs play a crucial role in the healing of peptic ulcers and
the management of conditions like Zollinger-Ellison syndrome, which involves
excessive gastric acid secretion. Their broad applicability across various
acid-related disorders has led to their widespread prescription and use,
contributing to their market dominance.
PPIs are supported by
extensive clinical research and evidence demonstrating their safety and efficacy.
Numerous studies have validated their effectiveness in managing acid-related
gastrointestinal conditions, leading to widespread acceptance among healthcare
providers. The established clinical track record of PPIs enhances their
credibility and encourages their continued use in clinical practice. This
strong evidence base, coupled with ongoing research into new formulations and
indications, reinforces their dominant position in the market. Branded PPIs,
such as omeprazole, esomeprazole, and lansoprazole, have achieved significant
market penetration and brand loyalty. These medications are often preferred by
healthcare providers due to their proven effectiveness and safety profiles.
Pharmaceutical companies behind these brands invest heavily in marketing,
education, and patient support programs, further strengthening their market
presence. The extensive marketing efforts and established brand reputation
contribute to the sustained dominance of PPIs in the gastrointestinal drugs
market.
Download Free Sample Report
Regional Insights
The Kanto region is the dominant force. This
region, which includes major metropolitan areas such as Tokyo and Yokohama,
plays a pivotal role in the market due to its large population, significant
healthcare infrastructure, and economic influence. The dominance of the Kanto
region is underpinned by several key factors that contribute to its leading
position in the gastrointestinal drugs market. The Kanto region, with Tokyo at
its core, is the most populous region in Japan, housing a substantial
proportion of the country's residents. Tokyo alone is one of the most populous
cities globally, and its large urban population drives a high demand for
healthcare services and medications. The dense population base translates into
a larger market for gastrointestinal drugs, as more people require treatment
for a range of gastrointestinal conditions. This high demand in a densely
populated area ensures that the Kanto region maintains a leading position in
the market.
The Kanto region boasts some of Japan's most
advanced healthcare infrastructure, including leading hospitals, research
institutions, and pharmaceutical companies. Tokyo, as the capital city, is a
hub for medical research and development, hosting numerous institutions that
contribute to the advancement of gastrointestinal therapeutics. The region's
healthcare facilities are equipped with state-of-the-art technology and staffed
by highly skilled professionals, facilitating the effective diagnosis and
treatment of gastrointestinal disorders. This robust healthcare infrastructure
supports the widespread use and availability of gastrointestinal drugs, further
solidifying the Kanto region's dominance in the market. The economic power of
the Kanto region, driven by Tokyo's status as Japan's economic center, also
plays a significant role in its dominance of the gastrointestinal drugs market.
The region's wealth and economic activity contribute to higher healthcare
spending and investment in pharmaceutical research and development.
Pharmaceutical companies are more likely to focus their efforts on the Kanto
region due to its economic significance, leading to a higher concentration of
innovative drugs and advanced treatments being available in this area.
The Kanto region is home to numerous pharmaceutical
companies and research institutions, fostering an environment of innovation and
development in the gastrointestinal drugs sector. Tokyo, in particular, serves
as a base for many major pharmaceutical firms that engage in extensive research
and development activities. This concentration of pharmaceutical expertise and
innovation means that the latest gastrointestinal drugs and therapies are more
readily accessible in the Kanto region. The presence of these companies also
drives competition and enhances the availability of cutting-edge treatments for
patients.
Recent Developments
- In June 2024, Sun Pharma
announced that it has entered into a non-exclusive patent licensing agreement
with the Japanese multinational Takeda Pharmaceutical Company Limited to launch
Voltapraz (Vonoprazan) in India. According to the company’s statement to the
exchanges, it will market Vonoprazan tablets in 10mg and 20mg dosages in India
under the brand name 'Voltapraz'. Sun Pharma highlighted that Vonoprazan is a
novel, orally-active potassium competitive acid blocker (PCAB) designed for
treating reflux esophagitis and various acid peptic disorders.
- In June 2023, Astellas
Pharma Inc. announced that it had submitted a New Drug Application (NDA) to
Japan's Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab. This
investigational monoclonal antibody, which targets Claudin 18.2 (CLDN18.2),
represents a novel class of treatment. The NDA seeks approval for zolbetuximab
as a first-line therapy for patients with locally advanced unresectable or
metastatic HER2-negative gastric or gastroesophageal junction (GEJ)
adenocarcinoma whose tumors are positive for CLDN18.2. If approved,
zolbetuximab would be the first CLDN18.2-targeted therapy available in Japan
for these patients.
- Astellas Pharma Inc.
announced that on March 26, 2024, Japan's Ministry of Health, Labour and
Welfare (MHLW) granted approval for VYLOY™ (zolbetuximab), an anti-claudin 18.2
(CLDN18.2) monoclonal antibody, for patients with CLDN18.2-positive,
unresectable, advanced, or recurrent gastric cancer. VYLOY is the first and
only CLDN18.2-targeted therapy to receive approval from any regulatory agency
globally.
Key Market Players
- AbbVie GK
- Novartis Pharma K.K.
- Santen Pharmaceutical Co., Ltd.
- Janssen Pharmaceuticals K.K.
- Senju Pharmaceutical Co., Ltd.
- Taisho Pharmaceutical Co., Ltd
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharma Japan Limited
- Asahi Kasei Pharma Corporation
- Kyowa Pharmaceutical Industry Co., Ltd.
|
By Type
|
By Drug Class
|
By Application
|
By Route Of Administration
|
By Distribution Channel
|
By Region
|
|
|
- Aminosalicylates
- Digestive enzymes
- Proton Pump Inhibitors
- Laxatives
- Anti-Emetics
- H2 Antagonists
- Anti-Diarrhea
- Biologics/Biosimilar
- Others
|
- Crohn’s Disease
- Ulcerative Colitis
- GERD
- IBS
|
|
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
|
- Hokkaido
- Tohoku
- Kanto
- Chubu
- Kansai
- Chugoku
- Shikoku
- Kyushu
|
Report Scope:
In this report, the Japan Gastrointestinal Drugs
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Japan Gastrointestinal Drugs
Market, By
Type:
o Branded
o Generics
- Japan Gastrointestinal Drugs
Market, By
Drug Class:
o Aminosalicylates
o Digestive enzymes
o Proton Pump Inhibitors
o Laxatives
o Anti-Emetics
o H2 Antagonists
o Anti-Diarrhea
o Biologics/Biosimilar
o Others
- Japan Gastrointestinal Drugs
Market, By
Application:
o Crohn’s Disease
o Ulcerative Colitis
o GERD
o IBS
- Japan Gastrointestinal Drugs
Market, By
Route of Administration:
o Oral
o Injectable
o Others
- Japan Gastrointestinal Drugs
Market, By
Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
- Japan Gastrointestinal Drugs
Market, By
Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Japan Gastrointestinal Drugs Market.
Available Customizations:
Japan Gastrointestinal Drugs Market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Japan Gastrointestinal Drugs Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]